Paraganglioma/ PhaeochromocytomaMelanoma and Other Malignant Neoplasms of SkinGastrointestinal Stromal Tumor (GIST)Adrenocortical TumorPancreatic TumorsEsthesioneuroblastoma, OlfactoryMesotheliomaNasopharyngeal Carcinoma (NPC)NUT CarcinomaPleuropulmonary BlastomaSalivary Gland TumorsThymic TumorsThyroid CarcinomaAppendiceal Cancers
Study summary
The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.
Eligibility
Sex
ALL
Min age
0 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria:
* Children and adolescents (age 0-18 years) with a primary or relapsed Very Rare Tumor diagnosed and/or treated in a participating country/center.
* Written informed consent from the patient and/or the parent/legal guardian
Exclusion Criteria:
* Absence of Written informed consent from the patient and/or the parent/legal guardian
Primary outcome measure(s)
Epidemiology — through study completion, an average of 1 year Evaluate the number of patients (aged 0-18 years) with different Very Rare Tumors in the different countries: observed cases will be compared with expected cases.
Use of International Recommendations — through study completion, an average of 1 year The study aims to measure the number of patients treated for different neoplasms in different countries, and the proportion of those treated in accordance with the International Recommendations.
Survival of children and adolescents (0-18 years) affected by Very Rare Tumors — through study completion, an average of 1 year The study will correlate the clinical characteristics of the tumor (size, site, extension) with the treatment, the risk of recurrence and survival.
Trial sites (1)
Facility
City
Region
Status
Pediatric Oncology Unit, University Hospital Padova [AOUP Azienda Ospedale Università Padova]
Padova
Italy
Recruiting
More Azienda Ospedaliera di Padova trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
